Celgene Corp. (CELG)

Revenue from the sale of products is recognized in a manner that depicts the transfer of those promised goods to customers in an amount that reflects the consideration to which Celgene expects to be entitled in exchange for these good or services. To achieve this core principle, Celgene follows a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, Celgene satisfies a performance obligation. In addition, Celgene recognizes revenue from other product sales and royalties based on licensees’ sales of the products or products using Celgene’s technologies. Celgene does not consider royalty revenue to be a material source of the consolidated revenue.

Celgene records gross-to-net sales accruals for government rebates, chargebacks, distributor services fees, other rebates and administrative fees, sales returns and allowances and sales discounts.

Source: 10-K (filing date: 2019-02-26).

Celgene Corp., Income Statement, Revenues

US$ in millions

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	REVLIMID®
	POMALYST®/IMNOVID®
	OTEZLA®
	ABRAXANE®
	IDHIFA®
	VIDAZA®
	Azacitidine for injection
	THALOMID®
	ISTODAX®
	Other
	Net product sales

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20).